TAVEGYL

This brand name is authorized in Germany, Ecuador, Estonia, Japan, Lithuania, Netherlands, Turkey

Active ingredients

The drug TAVEGYL contains one active pharmaceutical ingredient (API):

1 Clemastine UNII 19259EGQ3D - CLEMASTINE FUMARATE

Clemastine is an H1-receptor antagonist. It inhibits selectively the histamine receptors of the H1 type and reduces capillary permeability. It exerts a potent antihistaminic and antipruritic effect with a fast onset and long duration of action. Read about Clemastine

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
R06AA04	Clemastine	R Respiratory system → R06 Antihistamines for systemic use → R06A Antihistamines for systemic use → R06AA Aminoalkyl ethers
Discover more medicines within R06AA04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: DE	Bundesinstitut für Arzneimittel und Medizinprodukte	Identifier(s): 15607972, 15621386
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 25.954-09-04
Country: EE	Ravimiamet	Identifier(s): 1006333, 1006366, 1160761
Country: JP	医薬品医療機器総合機構	Identifier(s): 4419008B1073, 4419008B2070, 4419008F1431, 4419008Q1157
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1007827, 1007828, 1088248
Country: NL	Z-Index G-Standaard	Identifier(s): 14084805
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 507, 7560
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8681291010378, 8681291570384